Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

2.

Protective effects of a novel perfluorochemical emulsion in photodynamic therapy.

Lowe KC, Akande SL, Bonnett R, White RD, Berenbaum MC.

Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):925-7.

PMID:
1391535
3.

Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results.

Ris HB, Altermatt HJ, Inderbitzi R, Hess R, Nachbur B, Stewart JC, Wang Q, Lim CK, Bonnett R, Berenbaum MC, et al.

Br J Cancer. 1991 Dec;64(6):1116-20.

4.

Concepts for describing the interaction of two agents.

Berenbaum MC.

Radiat Res. 1991 May;126(2):264-8. No abstract available.

PMID:
2023997
5.
6.

Muscle damage and recovery in the rabbit tongue following photodynamic therapy with haematoporphyrin derivative.

Jefferis AF, Chevretton EB, Berenbaum MC.

Acta Otolaryngol. 1991;111(1):153-60.

PMID:
2014752
7.

Porphyrin sensitizers in tumour phototherapy. Novel sensitizers of the chlorin and bacteriochlorin class with amphiphilic properties.

Bonnett R, Nizhnik AN, White SG, Berenbaum MC.

J Photochem Photobiol B. 1990 Jun;6(1-2):29-37.

PMID:
2121938
8.

Direct search methods in the optimisation of cancer chemotherapy regimens.

Berenbaum MC.

Br J Cancer. 1990 Jan;61(1):101-9. Erratum in: Br J Cancer 1990 May;61(5):788.

9.

Perfluorochemicals and photodynamic therapy in mice.

Berenbaum MC, Akande SL, Armstrong FH, Bentley PK, Bonnett R, White RD, Lowe KC.

Adv Exp Med Biol. 1990;277:277-82.

PMID:
2096633
10.

Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers.

Bonnett R, White RD, Winfield UJ, Berenbaum MC.

Biochem J. 1989 Jul 1;261(1):277-80.

11.

The rabbit VX2 tumour as a model for carcinomas of the tongue and larynx.

Jefferis AF, Berenbaum MC.

Acta Otolaryngol. 1989 Jul-Aug;108(1-2):152-60.

PMID:
2763834
12.

What is synergy?

Berenbaum MC.

Pharmacol Rev. 1989 Jun;41(2):93-141. Review. No abstract available. Erratum in: Pharmacol Rev 1990 Sep;41(3):422.

PMID:
2692037
13.

Antagonism between radiosensitizing agents.

Berenbaum MC.

Br J Radiol. 1988 Oct;61(730):975-7. No abstract available.

PMID:
2973363
14.

Synergy and antagonism are not synonymous with therapeutic advantage and disadvantage.

Berenbaum MC.

J Antimicrob Chemother. 1988 Apr;21(4):497-500. No abstract available.

PMID:
3378962
15.

Anti-HIV synergy between dextran sulphate and zidovudine.

Berenbaum MC.

Lancet. 1987 Aug 22;2(8556):461. No abstract available.

PMID:
2442572
16.

Intrathecal interferon, indomethacin, and multiple sclerosis.

Berenbaum MC.

Lancet. 1987 Feb 7;1(8528):326-7. No abstract available.

PMID:
2880135
17.

Minor synergy and antagonism may be clinically important.

Berenbaum MC.

J Antimicrob Chemother. 1987 Feb;19(2):271-3. No abstract available.

PMID:
3571047
18.

meso-Tetra(hydroxyphenyl)porphyrins, a new class of potent tumour photosensitisers with favourable selectivity.

Berenbaum MC, Akande SL, Bonnett R, Kaur H, Ioannou S, White RD, Winfield UJ.

Br J Cancer. 1986 Nov;54(5):717-25.

19.
20.

Consequences of synergy between environmental carcinogens.

Berenbaum MC.

Environ Res. 1985 Dec;38(2):310-8.

PMID:
4065079
21.

Wavelength and light-dose dependence in tumour phototherapy with haematoporphyrin derivative.

van Gemert JC, Berenbaum MC, Gijsbers GH.

Br J Cancer. 1985 Jul;52(1):43-9.

22.

The expected effect of a combination of agents: the general solution.

Berenbaum MC.

J Theor Biol. 1985 Jun 7;114(3):413-31.

PMID:
4021503
23.

Synergy assessment with growth curves.

Berenbaum MC.

J Infect Dis. 1984 Aug;150(2):304. No abstract available.

PMID:
6470533
24.

Synergy with double and triple antibiotic combinations compared.

Berenbaum MC, Yu VL, Felegie TP.

J Antimicrob Chemother. 1983 Dec;12(6):555-63.

PMID:
6662835
25.

HPD - a study of its components and their properties.

Bonnett R, Berenbaum MC.

Adv Exp Med Biol. 1983;160:241-50. No abstract available.

PMID:
6220574
26.
27.

In vivo biological activity of the components of haematoporphyrin derivative.

Berenbaum MC, Bonnett R, Scourides PA.

Br J Cancer. 1982 Apr;45(4):571-81.

28.

Neutrophil function during chemotherapy for Hodgkin's disease.

Gandossini M, Souhami RL, Babbage J, Addison IE, Johnson AL, Berenbaum MC.

Br J Cancer. 1981 Dec;44(6):863-71.

29.

Criteria for analyzing interactions between biologically active agents.

Berenbaum MC.

Adv Cancer Res. 1981;35:269-335. Review. No abstract available.

PMID:
7041539
30.

Correlations between methods for measurement of synergy.

Berenbaum MC.

J Infect Dis. 1980 Sep;142(3):476-80. No abstract available.

PMID:
7003034
31.

Research ethics and deception.

Berenbaum MC.

Lancet. 1980 Apr 5;1(8171):772. No abstract available.

PMID:
6103192
32.

Subcutaneous Corynebacterium parvum in bladder cancer: a controlled study of its immunological effects.

Purves EC, Snell M, Cope WA, Addison IE, Copland RF, Berenbaum MC.

Br J Urol. 1979 Aug;51(4):278-82.

PMID:
380732
33.
34.

The immunosuppressive effects of 5-fluorocytosine and 5-fluorouracil.

Berenbaum MC.

Chemotherapy. 1979;25(1):54-9.

PMID:
421598
35.

A method for testing for synergy with any number of agents.

Berenbaum MC.

J Infect Dis. 1978 Feb;137(2):122-30.

PMID:
627734
36.

Synergy, additivism and antagonism in immunosuppression. A critical review.

Berenbaum MC.

Clin Exp Immunol. 1977 Apr;28(1):1-18. Review. No abstract available.

37.
38.

Intercellular immunological controls and modulation of cyclic AMP levels. Some doubts.

Berenbaum MC, Purves EC, Addison IE.

Immunology. 1976 Jun;30(6):815-23.

39.

Selective suppression of murine antibody-dependent cell-mediated cytotoxicity by azathioprine.

Purves EC, Berenbaum MC.

Transplantation. 1975 Mar;19(3):274-6. No abstract available.

PMID:
1094641
40.

Photodynamic destruction of human bladder carcinoma.

Kelly JF, Snell ME, Berenbaum MC.

Br J Cancer. 1975 Feb;31(2):237-44.

41.

Letter: Predicting response of human cancer to chemotherapy.

Berenbaum MC.

Lancet. 1974 Nov 9;2(7889):1141-2. No abstract available.

PMID:
4139436
42.

Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide.

O'Connell TX, Berenbaum MC.

Cancer Res. 1974 Jul;34(7):1586-91. No abstract available.

43.

The growth of human tumours in immunosuppressed mice and their response to chemotherapy.

Berenbaum MC, Sheard CE, Reittie JR, Bundick RV.

Br J Cancer. 1974 Jul;30(1):13-32.

44.

Depression of lymphocyte responses after surgical trauma.

Berenbaum MC, Fluck PA, Hurst NP.

Br J Exp Pathol. 1973 Dec;54(6):597-607. No abstract available.

45.

Differential asparaginase sensitivity of T-cell and B-cell responses.

Berenbaum MC, Cope WA, Jeffery W.

Clin Exp Immunol. 1973 Dec;15(4):565-72. No abstract available.

46.

The effect of microsomal enzyme inhibition on the immunosuppressive and toxic effects of cyclophosphamide.

Berenbaum MC, Cope WA, Double JA.

Clin Exp Immunol. 1973 Jun;14(2):257-70. No abstract available.

47.

In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents.

Berenbaum MC.

Cancer Chemother Rep. 1972 Oct;56(5):563-71. No abstract available.

PMID:
4652587
48.

Immunosuppressive agents: generation and consequences of differing dose-response curves.

Berenbaum MC.

Proc R Soc Med. 1972 Mar;65(3):255-7. No abstract available.

49.

Growth of human and rat tumours in immunosuppressed mice.

Berenbaum MC, Sheard CE, Double JA.

J Pathol. 1972 Jan;106(1):Pxi. No abstract available.

PMID:
5035763
50.

The sensitivity to chemotherapeutic agents of a rat tumour grown in immunosuppressed mice.

Sheard CE, Double JA, Berenbaum MC.

Br J Cancer. 1971 Dec;25(4):838-44.

Supplemental Content

Loading ...
Support Center